These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

73 related articles for article (PubMed ID: 9586607)

  • 1. Percentage of free serum prostate-specific antigen as a predictor of pathologic features of prostate cancer in a screening population.
    Arcangeli CG; Humphrey PA; Smith DS; Harmon TJ; Shepherd DL; Keetch DW; Catalona WJ
    Urology; 1998 Apr; 51(4):558-64; discussion 564-5. PubMed ID: 9586607
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Percent free PSA as an additional measure in a prostate cancer screen.
    Miele ME
    Clin Lab Sci; 2001; 14(2):102-7. PubMed ID: 15625982
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Diagnostic value of free prostate-specific antigen among men with a prostate-specific antigen level of <3.0 microg per liter.
    Finne P; Auvinen A; Määttänen L; Tammela TL; Ruutu M; Juusela H; Martikainen P; Hakama M; Stenman UH
    Eur Urol; 2008 Aug; 54(2):362-70. PubMed ID: 18006214
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Electrophoretic subforms of free prostate-specific antigen in serum as promising diagnostic tool in prostate cancer diagnostics.
    Jung K; Hoesel W; Reiche J; Deger S; Kramer J; Loening SA; Lein M; Stephan C
    Urology; 2007 Feb; 69(2):320-5. PubMed ID: 17320672
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Preoperative serum prostate specific antigen does not reflect biochemical failure rates after radical prostatectomy in men with large volume cancers.
    Noguchi M; Stamey TA; McNeal JE; Yemoto CM
    J Urol; 2000 Nov; 164(5):1596-600. PubMed ID: 11025712
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Relationship between systematic biopsies and histological features of 222 radical prostatectomy specimens: lack of prediction of tumor significance for men with nonpalpable prostate cancer.
    Noguchi M; Stamey TA; McNeal JE; Yemoto CM
    J Urol; 2001 Jul; 166(1):104-9; discussion 109-10. PubMed ID: 11435833
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of predictive accuracy for pathologically organ confined clinical stage T1c prostate cancer using human glandular kallikrein 2 and prostate specific antigen combined with clinical stage and Gleason grade.
    Haese A; Vaisanen V; Lilja H; Kattan MW; Rittenhouse HG; Pettersson K; Chan DW; Huland H; Sokoll LJ; Partin AW
    J Urol; 2005 Mar; 173(3):752-6. PubMed ID: 15711262
    [TBL] [Abstract][Full Text] [Related]  

  • 8. hK2 and free PSA, a prognostic combination in predicting minimal prostate cancer in screen-detected men within the PSA range 4-10 ng/ml.
    Raaijmakers R; de Vries SH; Blijenberg BG; Wildhagen MF; Postma R; Bangma CH; Darte C; Schröder FH
    Eur Urol; 2007 Nov; 52(5):1358-64. PubMed ID: 17499425
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Early diagnosis of prostate cancer using free/total prostate-specific antigen ratio with population-based screening data].
    Zhang L; Ji G; Li X; Wang W; Gao H; Pan Y; Wang H; Masaaki K; Zhao X
    Zhonghua Nan Ke Xue; 2004 Aug; 10(8):582-5. PubMed ID: 15362518
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prostate specific antigen density correlates with features of prostate cancer aggressiveness.
    Kundu SD; Roehl KA; Yu X; Antenor JA; Suarez BK; Catalona WJ
    J Urol; 2007 Feb; 177(2):505-9. PubMed ID: 17222621
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Preoperative PSA is still predictive of cancer volume and grade in late PSA era.
    Figler BD; Reuther AM; Dhar N; Levin H; Magi-Galluzzi C; Zhou M; Klein EA
    Urology; 2007 Oct; 70(4):711-6. PubMed ID: 17991542
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Body mass index does not predict prostate-specific antigen or percent free prostate-specific antigen in men undergoing prostate cancer screening.
    Hutterer G; Perrotte P; Gallina A; Walz J; Jeldres C; Traumann M; Suardi N; Saad F; Bénard F; Valiquette L; McCormack M; Graefen M; Montorsi F; Karakiewicz PI
    Eur J Cancer; 2007 May; 43(7):1180-7. PubMed ID: 17292604
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PSA in the new millennium: a powerful predictor of prostate cancer prognosis and radical prostatectomy outcomes--results from the SEARCH database.
    Freedland SJ; Hotaling JM; Fitzsimons NJ; Presti JC; Kane CJ; Terris MK; Aronson WJ; Amling CL
    Eur Urol; 2008 Apr; 53(4):758-64; discussion 765-6. PubMed ID: 17868976
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical and pathologic outcome after radical prostatectomy for prostate cancer patients with a preoperative Gleason sum of 8 to 10.
    Bastian PJ; Gonzalgo ML; Aronson WJ; Terris MK; Kane CJ; Amling CL; Presti JC; Mangold LA; Humphreys E; Epstein JI; Partin AW; Freedland SJ
    Cancer; 2006 Sep; 107(6):1265-72. PubMed ID: 16900523
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of precursor prostate-specific antigen isoform ratios in the detection of prostate cancer.
    Naya Y; Fritsche HA; Bhadkamkar VA; Mikolajczyk SD; Rittenhouse HG; Babaian RJ
    Urol Oncol; 2005; 23(1):16-21. PubMed ID: 15885578
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prospective characterization of pathological features of prostatic carcinomas detected via serum prostate specific antigen based screening.
    Humphrey PA; Keetch DW; Smith DS; Shepherd DL; Catalona WJ
    J Urol; 1996 Mar; 155(3):816-20. PubMed ID: 8583583
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of proprostate specific antigen for early detection of prostate cancer in men with a total prostate specific antigen range of 4.0 to 10.0 ng/ml.
    Khan MA; Partin AW; Rittenhouse HG; Mikolajczyk SD; Sokoll LJ; Chan DW; Veltri RW
    J Urol; 2003 Sep; 170(3):723-6. PubMed ID: 12913682
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Histopathological prostate cancer characteristics at radical prostatectomy after population based screening.
    Hoedemaeker RF; Rietbergen JB; Kranse R; Schröder FH; van der Kwast TH
    J Urol; 2000 Aug; 164(2):411-5. PubMed ID: 10893598
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Preoperative prediction of final pathological features is not improved by the free-to-total prostate-specific antigen ratio in Japanese men with clinically localized prostate cancer.
    Miyake H; Sakai I; Harada K; Hara I; Eto H
    Int J Urol; 2005 Feb; 12(2):182-6. PubMed ID: 15733113
    [TBL] [Abstract][Full Text] [Related]  

  • 20. PSA-related markers in the detection of prostate cancer and high-grade disease in the contemporary era with extended biopsy.
    Bratslavsky G; Fisher HA; Kaufman RP; Voskoboynik D; Nazeer T; Mian BM
    Urol Oncol; 2008; 26(2):166-70. PubMed ID: 18312936
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.